Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara-Reference-Cited by-同舟云学术

Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara

Published:2016-08-30 Issue:1 Volume:15 Page:
ISSN:1475-2875
Container-title:Malaria Journal
language:en
Short-container-title:Malar J

Author:

Thera Mahamadou A.,Coulibaly Drissa,Kone Abdoulaye K.,Guindo Ando B.,Traore Karim,Sall Abdourhamane H.,Diarra Issa,Daou Modibo,Traore Idrissa M.,Tolo Youssouf,Sissoko Mady,Niangaly Amadou,Arama Charles,Baby Mounirou,Kouriba Bourema,Sissoko Mahamadou S.,Sagara Issaka,Toure Ousmane B.,Dolo Amagana,Diallo Dapa A.,Remarque Edmond,Chilengi Roma,Noor Ramadhani,Sesay Sanie,Thomas Alan,Kocken Clemens H.,Faber Bart W.,Imoukhuede Egeruan Babatunde,Leroy Odile,Doumbo Ogobara K.

Funder

African Malaria Network Trust

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Parasitology

Link

http://link.springer.com/content/pdf/10.1186/s12936-016-1466-4

Reference34 articles.

1. WHO. World Malaria Report 2015. Geneva: World Health Organization; 2015.

2. Breman JG, Plowe CV. A malaria vaccine for control: more progress. J Infect Dis. 2009;200:317–20.

3. Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, Assadou MH, et al. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS ONE. 2007;2:e1045.